Key Product Details
Structure / Form
Accession # XP_005550047.1
N-terminal Sequence Analysis
Predicted Molecular Mass
When Recombinant Human Integrin alphaV beta3 (Catalog # 3050-AV) is immobilized at 2 µg/mL (100 µL/well), Recombinant Cynomolgus Monkey/Rhesus Macaque Osteoactivin/GPNMB Fc Chimera (Catalog # 11154-AC) binds with an ED50 of 0.750-9.00 µg/mL.
Scientific Data Images for Recombinant Cyno/Rhesus Osteoactivin/GPNMB Fc Protein, CF
Recombinant Cynomolgus/Rhesus Osteoactivin/GPNMB Fc Chimera Protein SDS-PAGE.2 μg/lane of Recombinant Cynomolgus/Rhesus Osteoactivin/GPNMB Fc Chimera Protein (Catalog # 11154-AC) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 111-122 kDa and 220-245 kDa, respectively.
Formulation, Preparation and Storage
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Osteoactivin (also GPNMB and DC-HIL) is a variably glycosylated 75 - 125 kDa member of the NMB/pMEL-17 family of molecules. It is found in multiple subcellular sites, but is most often associated with the endosomal/lysosomal compartment (1, 2, 3). Human Osteoactivin is a 560 amino acid (aa) type I transmembrane protein. Its precursor contains a 21 aa signal sequence, a 465 aa luminal/extracellular domain, a 21 aa transmembrane segment and a 53 aa cytoplasmic tail (4, 5). The luminal region contains an N-terminal heparin-binding motif (aa 23 - 26), multiple glycosylation sites, an RGD motif (aa 64 - 66) and an 88 aa PKD domain (aa 240 - 327). The intracellular tail has an ITAM (Y-x-x-I) and lysosomal targeting (L-L) motif (4, 5). The extracellular/luminal region shares 94% aa identity between human and cynomolgus monkey Osteoactivin. Multiple isoforms would appear to exist. There is one alternate splice form known that shows a 12 aa insert between aa 339 - 340 (6). An addtional 206 aa isoform shows a mutation at position # 181 that results in a 26 aa substitution for the C-terminal 380 amino acids (7, 8). This has the potential to be soluble and may represent a counterpart to a secreted isoform of rat Osteoactivin (9). Cells known to express Osteoactivin include macrophages/Kupffer cells, fibroblasts, osteoblasts, myeloid dendritic cells, retinal pigment epithelial cells and melanocytes, plus fetal chondrocytes and stratum basale keratinocytes (3, 4, 5, 10, 11, 12). In mice, Osteoactivin is reported to bind to heparan sulfate-proteoglycan, possibly on the surface of endothelial cells and may also interact with integrins (13). It also appears to act as an inflammatory suppressor gene, as its expression downregulates the macrophage inflammatory response by inhibiting IL-6 and IL-12p40 production (3).
- Bachner, D. et al. (2002) Gene Exp. Patterns 1:159.
- Safadi, F.F. et al. (2002) J. Cell. Biochem. 84:12.
- Ripoll, V.M. et al. (2007) J. Immunol. 178:6557.
- Owen, T.A. et al. (2003) Crit. Rev. Eukaryot. Gene Expr. 13:205.
- Weterman, M.A.J. et al. (1995) Int. J. Cancer 60:73.
- Kuan, C-T. et al. (2006) Clin. Cancer Res. 12:1970.
- Lennerz, V. et al. (2005) Proc. Natl. Acad. Sci. USA 102:16013.
- Genbank Accession # AAH11595.
- Abdelmagid, S.M. et al. (2007) J. Cell. Physiol. 210:26.
- Haralanova-Ilieva, B. et al. (2005) J. Hepatol. 42:565.
- Ahn, J.H. et al. (2002) Blood 100:1742.
- Anderson, M.G. et al. (2002) Nat. Genet. 30:81.
- Shikano, S. et al. (2001) J. Biol. Chem. 276:8125.
Product Specific Notices for Recombinant Cyno/Rhesus Osteoactivin/GPNMB Fc Protein, CF
For research use only